Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase
Author:
- 1 March 2007
- journal article
- editorial
- Published by Wiley in British Journal of Pharmacology
- Vol. 150 (5) , 538-540
Abstract
During the past 18 years, sildenafil has evolved from a potential anti‐angina drug to an on‐demand treatment for erectile dysfunction and more recently to a new orally active treatment for pulmonary hypertension. Recent studies suggest that the drug has powerful cardioprotective effect against ischemia/reperfusion injury, doxorubicin‐induced cardiomyopathy and anti‐hypertensive effect induced by chronic inhibition of nitric oxide synthase in animals. Based on several recent basic and clinical studies, it is clear that sildenafil and other clinically approved type‐5 phosphodiesterase‐5 inhibitors including vardenafil and tadalafil will eventually be developed for several cardiovascular indications including essential hypertension, endothelial dysfunction, ischemia/reperfusion injury, myocardial infarction, ventricular remodeling and heart failure.British Journal of Pharmacology (2007) 150, 538–540. doi:10.1038/sj.bjp.0707132Keywords
This publication has 24 references indexed in Scilit:
- Sildenafil reduces L‐NAME‐induced severe hypertension and worsening of myocardial ischaemia–reperfusion damage in the ratBritish Journal of Pharmacology, 2007
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbitsJournal of Molecular and Cellular Cardiology, 2007
- Effect of Regular Phosphodiesterase Type 5 Inhibition in HypertensionHypertension, 2006
- The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct sizeInternational Journal Of Impotence Research, 2006
- Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbitsJournal of Molecular and Cellular Cardiology, 2006
- Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin CardiotoxicityCirculation, 2005
- Sildenafil Prevents Endothelial Dysfunction Induced by Ischemia and Reperfusion via Opening of Adenosine Triphosphate–Sensitive Potassium ChannelsCirculation, 2005
- Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogsBritish Journal of Pharmacology, 2004
- Sildenafil Induces Delayed Preconditioning Through Inducible Nitric Oxide Synthase–Dependent Pathway in Mouse HeartCirculation Research, 2003
- Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failureThe FASEB Journal, 2001